Advertisement
Advertisement
NBTX
Nanobiotix S.A. - ADR
38.22
USDSponsored
+0.43
+1.14%
Aug 07, 15:58 UTC -4
Closed
After-Market
37.96
-0.26
-0.68%
NBTX Earnings Reports
Positive Surprise Ratio
NBTX beat 4 of 16 last estimates.
25%
Next Report
Date of Next Report
Sep 28, 2026
Estimate for Q2 26 (Revenue/ EPS)
$30.50M
/-$0.11
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q2 25 (Revenue/ EPS)
+14.49%
/--
Nanobiotix S.A. - ADR earnings per share and revenue
On May 19, 2026, NBTX reported earnings of -- USD per share (EPS) for Q1 26, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q2 26, 3 analysts forecast an EPS of -0.11 USD, with revenue projected to reach 30.50 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
FAQ
What were Nanobiotix S.A. - ADR's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Nanobiotix S.A. - ADR reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Nanobiotix S.A. - ADR's Q1 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Nanobiotix S.A. - ADR expected to report next?
The next earning report is scheduled for Sep 28, 2026.
What are the forecasts for Nanobiotix S.A. - ADR's next earnings report?
Based on 3
analysts, Nanobiotix S.A. - ADR is expected to report EPS of -$0.11 and revenue of $30.50M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement